Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 574 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-Alcoholic Steatohepatitis Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT01289639
View directory record Official record
Conditions
Fatty Liver
Interventions
fenofibrate, pioglitazone, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 6, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional

Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT03676231
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SGM-1019, Placebo
Drug
Lead sponsor
Second Genome
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Chandler, Arizona • Tucson, Arizona • Panorama City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 6, 2026, 4:12 PM EDT
Terminated Phase 3 Interventional Results available

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

NCT02548351
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Obeticholic Acid, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Not applicable Interventional

Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease

NCT06215131
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic, Weight Loss, Virtual Reality, Implementation Science
Interventions
In-person dietary weight loss counseling, Virtual reality dietary weight loss counseling
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Early Phase 1 Interventional Results available

Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease

NCT00949403
View directory record Official record
Conditions
Fatty Liver
Interventions
Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 6, 2026, 4:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease

NCT05209100
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Sigmoidoscopy
Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
35 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT03261739
View directory record Official record
Conditions
NAFLD
Interventions
RYI-018, Placebo
Biological
Lead sponsor
Bird Rock Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 6, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional Results available

Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

NCT00529204
View directory record Official record
Conditions
Diabetes Complications, Fatty Liver
Interventions
exenatide
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

NCT05680233
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Interventions
OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg), OA-235i (30 mg), OA-235i (40 mg), OA-235i or placebo
Drug
Lead sponsor
Oasis Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Oral Proglumide for NASH

NCT04152473
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Proglumide
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

NCT05327127
View directory record Official record
Conditions
NASH
Interventions
K-877-ER, CSG452, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
37
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lincoln, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Phase 2b Study in NASH to Assess IVA337

NCT03008070
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Madison, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)

NCT02633956
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Obeticholic Acid, Atorvastatin, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
22
States / cities
Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Treating Nonalcoholic Steatohepatitis With Pioglitazone

NCT00062764
View directory record Official record
Conditions
Hepatitis
Interventions
Actos (Pioglitazone)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 6, 2026, 4:12 PM EDT
Enrolling by invitation Not applicable Interventional

Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED

NCT06944353
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Steatosis of Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
STIRRED
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4,704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 6, 2026, 4:12 PM EDT
Completed No phase listed Observational

Non Alcoholic Fatty Liver Disease and Coronary Heart Disease in Type 2 Diabetes Patients

NCT04462081
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

NCT02927184
View directory record Official record
Conditions
Hyperlipidemia, NAFLD
Interventions
VK2809, Placebo
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Chandler, Arizona • Garden Grove, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 6, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05282121
View directory record Official record
Conditions
Liver Diseases, Hypertension, Portal
Interventions
Avenciguat, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Pasadena, California • Rialto, California • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 4 Interventional Results available

Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment

NCT01002547
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
pioglitazone-placebo, pioglitazone, Vitamin E, Vitamin E-placebo
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 6, 2026, 4:12 PM EDT
Terminated Phase 3 Interventional

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

NCT00577148
View directory record Official record
Conditions
Fatty Liver
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 6, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional Results available

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

NCT02855164
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor (LJN452), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
31
States / cities
Madison, Alabama • North Little Rock, Arkansas • Coronado, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Not applicable Interventional

Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease

NCT01327443
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy

NCT01679197
View directory record Official record
Conditions
Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis, Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 6, 2026, 4:12 PM EDT